MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

BioMarin Pharmaceutical Inc

Fermé

SecteurSoins de santé

67.41 -1.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

66.74

Max

68.31

Chiffres clés

By Trading Economics

Revenu

19M

125M

Ventes

1.6M

747M

P/E

Moyenne du Secteur

31.986

63.778

BPA

0.92

Marge bénéficiaire

16.719

Employés

3,040

EBITDA

39M

195M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+45.48% upside

Dividendes

By Dow Jones

Prochains Résultats

23 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.6B

14B

Ouverture précédente

68.84

Clôture précédente

67.41

Sentiment de l'Actualité

By Acuity

11%

89%

10 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 juin 2024, 17:41 UTC

Principaux Mouvements du Marché

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21 août 2024, 11:30 UTC

Actualités

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Comparaison

Variation de prix

BioMarin Pharmaceutical Inc prévision

Objectif de Prix

By TipRanks

45.48% hausse

Prévisions sur 12 Mois

Moyen 99.39 USD  45.48%

Haut 127 USD

Bas 70 USD

Basé sur 24 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

24 ratings

19

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

67.835 / 71.32Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

10 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.